🍪 The GLP Lounge uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsPublic SquareCan someone explain this to me like I am five? — anyone have experience? Page 2

Can someone explain this to me like I am five? — anyone have experience?

SteveThurs Thu, Dec 5, 2024 at 10:48 PM 7 replies 1,657 viewsPage 2 of 2
Dr.ObesityMed
VIP Member
3,456
19,234
Nov 2023
Denver, CO
Online
Dec 7, 2024 at 12:26 AM#6
COA_Karl said:
Read four things before the headline number.

This is where I part company with the consensus forming above. I would add the less popular caveat: these trial populations under-represented several groups, older adults and the highest BMI categories among them. The results probably generalise, and "probably" should be stated as an assumption rather than dropped.

Last edited: Dec 7, 2024 at 6:26 AM
23 1EndoResFellow, PharmacoVig_BOS, SurmountFan_IN and 20 others
Reply Quote Save Share Report
labquiet_amy
Senior Member
1,234
6,789
Mar 2024
Cambridge, MA
Dec 7, 2024 at 10:40 AM#7
SteveThurs said:
My own curve sits about four points below the published mean and I spent two months assuming that meant something was wrong with me or with my…

Propensity score matching studies and the trial evidence: when RCTs aren't available for a specific question, propensity score-matched observational studies can provide useful evidence.

A recent PSM study of 25,000 GLP-1 users vs matched controls showed reduced all-cause mortality (HR 0.81) over 5 years of follow-up[1].

These results complement the RCT data and suggest the benefits translate to real-world populations.

References:
[1] Registry-based cohort study, pre-print 2024.
24 2HPLC_Greg, LibrarianMeg, bri_stats and 21 others
Reply Quote Save Share Report
Dr.RenalNash
VIP Member
1,234
7,890
Mar 2024
Nashville, TN
Dec 7, 2024 at 8:54 PM#8
Dr.ObesityMed said:
I would add the less popular caveat: these trial populations under-represented several groups, older adults and the highest BMI categories among them.

Bayesian meta-analysis perspective on the trial evidence: traditional frequentist meta-analyses report point estimates and confidence intervals. Bayesian approaches provide probability distributions that are more intuitive for clinical decision-making.

For example: "There is a 98.5% probability that semaglutide 2.4mg produces >10% weight loss vs placebo" is more actionable than "RR 3.4, 95% CI 2.8-4.1, p<0.001."

The the trial evidence evidence is strong under both frameworks, but Bayesian analysis better communicates the degree of certainty for individual patient counseling.

25 3Dr.NutriCornell, pam_stl, wei_SG and 22 others
Reply Quote Save Share Report

PeptideMeter — Independent Peptide Analytics

Community-driven peptide testing and vendor rating platform. Transparent results. Unbiased analysis. Trusted by thousands.

View Results
matt_MKE
Member
312
1,345
Sep 2024
Milwaukee, WI
Dec 8, 2024 at 7:08 AM#9

Following on from Dr.PeteFamMed — and this may be the naive question:

What would you measure differently if you were starting again?

26 4carl_compliance, DanielChem_CHI, marco_milano and 23 others
Reply Quote Save Share Report
SteveThurs
Member
523
2,345
Sep 2024
Wisconsin
Online
Dec 10, 2024 at 8:16 AM#10

Reporting back.

Update — my curve sits below the published mean and the explanation is that the trial arm had support I do not have. That was reassuring rather than otherwise.

6 6TomTeleRx, DoseLogDan, SleepFixSam and 3 others
Reply Quote Save Share Report

Similar Threads

SELECT trial 4-year follow-up data released — sustained MACE reduction16 replies
GLP-1 receptor agonists and thyroid C-cell concerns — evidence review19 replies
Is there a ceiling effect for GLP-1-mediated weight loss?20 replies
Comparative pharmacokinetics: semaglutide vs tirzepatide vs retatrutide6 replies
My 18-month semaglutide journey — comprehensive data log20 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register